Trials / Conditions / DS Stage III Plasma Cell Myeloma

DS Stage III Plasma Cell Myeloma

13 registered clinical trials studyying DS Stage III Plasma Cell Myeloma.

Status	Trial	Sponsor	Phase
Terminated	Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoi NCT01899326	Albert Einstein College of Medicine	N/A
Completed	Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multip NCT01936090	Mayo Clinic	Phase 1
Completed	Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma NCT01842308	Mayo Clinic	Phase 1 / Phase 2
Unknown	NK Cells in Cord Blood Transplantation NCT01619761	M.D. Anderson Cancer Center	Phase 1
Active Not Recruiting	S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly D NCT01668719	SWOG Cancer Research Network	Phase 1 / Phase 2
Completed	Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple NCT01605032	Albert Einstein College of Medicine	Phase 2
Withdrawn	RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma NCT01251172	National Cancer Institute (NCI)	Phase 2
Completed	Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple NCT01330173	National Cancer Institute (NCI)	Phase 1
Terminated	Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01028716	Fred Hutchinson Cancer Center	Phase 2
Completed	Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell T NCT00839956	Fred Hutchinson Cancer Center	Phase 2
Completed	Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant f NCT00445692	Fred Hutchinson Cancer Center	Phase 2
Completed	Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Sy NCT00088855	National Cancer Institute (NCI)	Phase 2
Completed	FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma NCT00066638	National Cancer Institute (NCI)	Phase 2